Major study compares transplant vs. standard care for rare immune disease
NCT ID NCT02116764
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This study looked at 137 people with Chronic Granulomatous Disease (CGD), a rare immune disorder. It compared those who received a stem cell transplant with those who got standard care. The goal was to see which patients benefit most from transplant and what type of transplant works best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Gene fix for rare immune disease: can it stop deadly infections?
- Groundbreaking gene therapy aims to fix immune system in rare disease
- New hope for CGD: stem cell transplant trial aims for a cure
- Milder stem cell transplant shows promise for kids with immune disorders
- Scientists dig into immune cells to unlock lung disease mysteries